Clinical trials: Patients With Tumor
Sarcoma, Alveolar Soft Part Sarcoma (ASPS)
CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma
A single patient study to determine whether GCAR1 is safe and effective for re-treatment of alveolar soft part sarcoma (ASPS) with GPNMB surface expression that has relapsed and is not responding to usual treatment.
- Trial name
- SPS-Q2 (NCT06813417)
- Testing
- GCAR1
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Advanced Cancer, Nausea
DAnish Nausea Study In Advanced Cancer-Epidemiology: A Danish Multicenter Trial to Investigate the Prevalence and Treatment of Nausea and/or Vomiting in Patients With Advanced Cancer.
The study aims to investigate the prevalence and treatment of nausea and/or vomiting in patients with advanced cancer not receiving chemotherapy or irradiation.
- Conditions
- Advanced Cancer, Nausea, Emesis
- Trial name
- NCT02980289
- Where
- Denmark
- Volunteers
- 821 people
- Sponsor
- Signe Harder
Advanced Solid Tumors
Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial, which aims to observe and evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of HRS2398…
- Trial name
- NCT06439589
- Testing
- HRS2398, Adebrelimab
- Where
- 2 sites in China
- Volunteers
- 88 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumor
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors
This is the first in human study of BL0020, and the primary objective is to evaluate the safety and tolerability, and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of BL0020 as a single agent in…
- Trial name
- NCT05886868
- Testing
- BL0020
- Where
- 4 sites in Australia, China
- Volunteers
- 66 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Lymphoma, B-Cell
External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma
The purpose of the research study is to learn whether external beam radiation can be used as a safe and effective treatment for patients with bulky (≥ 5cm) sites of non-Hodgkin's lymphoma prior to treatment with 90Y-ibritumomab…
- Trial name
- NCT00271050
- Testing
- external beam radiotherapy plus 90-Y ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Cleveland Clinic
Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with carboplatin and to see how well they work in treating patients with human epidermal growth factor 2 (HER2)-negative breast cancer…
- Conditions
- Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01251874
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus
This study evaluates the immune response for patients affected by metastatic breast cancer treated by everolimus
- Trial name
- EVERIMMUN (NCT02854618)
- Testing
- additional blood sample
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
This phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia.
- Trial name
- NCT00866918
- Testing
- Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis
- Where
- 121 sites in United States, Canada and 1 more
- Volunteers
- 106 people
- Sponsor
- Children's Oncology Group
Solid Tumor, Adult, Relapsed Cancer
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of…
- Conditions
- Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05662397
- Testing
- HST-1011, Cemiplimab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 77 people
- Sponsor
- HotSpot Therapeutics, Inc
Prostate Cancer
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when…
- Trial name
- NCT00035997
- Testing
- Zometa
- Where
- 56 sites in United States
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Disease, Diabetes
Pragmatic Randomized Control Trial of Telehealth vs Standard Care in Follow-up of Patients With Chronic Conditions
The Norwegian health authorities has initiated a three-year trial of telehealth solutions as part of the treatment of patients with chronic illness in the period 2018-2021.
- Conditions
- Chronic Disease, Diabetes, Vascular Diseases, Chronic Lung Disease
- Trial name
- MAO (NCT04142710)
- Testing
- Telemedicine: tablet and possibly tools to perform measurements
- Where
- 9 sites in Norway
- Volunteers
- 732 people
- Sponsor
- University of Oslo
Non Small Cell Lung Cancer
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
This is a single center, open-label, nonrandomized, phase 1b, dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
- Trial name
- NCT03780010
- Testing
- TRC105
- Volunteers
- 15 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Melanoma (Skin)
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from…
- Trial name
- NCT00118313
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim
- Where
- United States
- Sponsor
- Craig L Slingluff, Jr
Prostate Cancer
Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial Chemoembolization With Doxorubicin in Prostate Cancer Patients Before Radical Prostatectomy
Our hypothesis is that the doxorubicin eluting-beads currently used in hepato-oncology might be applicable to high-grade prostate cancer before radical prostatectomy.
- Trial name
- CAPEMCHAR (NCT04423913)
- Testing
- Administration of embolization beads
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cancer
Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy
The purpose of this study is to collect blood samples, as well as tumor tissue for genetic analysis. The collection of samples will allow the creation of a plasma bank.
- Trial name
- Plasma-Target (NCT03835520)
- Testing
- Immunotherapeutic Agent, Molecular Target
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Osteosarcoma
Monocyte Phenotypic and Functional Differences
The purpose of this study is to identify phenotypic (cell surface receptor expression) and functional differences in monocyte populations in humans with osteosarcoma as compared to published historical data on normal human…
- Trial name
- NCT02132182
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Sarcoma
BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma
Phase I/II trial to study the effectiveness of BMS-275291 in treating patients who have HIV-related Kaposi's sarcoma. Drugs such as BMS-275291 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
- Trial name
- NCT00024024
- Testing
- rebimastat
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.
- Trial name
- NCT06066424
- Testing
- Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease
RATIONALE: Antiemetic drugs such as granisetron may help to prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of granisetron with that of a placebo…
- Trial name
- NCT00005024
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Sponsor
- Jonsson Comprehensive Cancer Center
Triple Negative Breast Neoplasms
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
- Trial name
- CAPItello-290 (NCT03997123)
- Testing
- Capivasertib, Paclitaxel
- Where
- 260 sites in United States, Argentina and 28 more
- Volunteers
- 923 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.